MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- NEULAND LABS (pharmaceuticals)
- Latest 8 Quarter Result
NEULAND LABS Quarterly Results (NELB)
Here are the latest quarterly results of NEULAND LABS. For more details, see the NEULAND LABS financial fact sheet and NEULAND LABS share price and chart. For a sector overview, read our pharmaceuticals sector report.
NEULAND LABS Quarterly Results
| No. of Mths Qtr. Ending |
3
Mar-19 |
3
Jun-19 |
3
Sep-19 |
3
Dec-19 |
3
Mar-20 |
3
Jun-20 |
3
Sep-20 |
3
Dec-20 |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 1,727 | 1,810 | 1,862 | 2,036 | 1,919 | 2,054 | 2,414 | 2,454 | |
| Other income | Rs m | 13 | 5 | 6 | 10 | 18 | 7 | 6 | 2 | |
| Turnover | Rs m | 1,740 | 1,815 | 1,868 | 2,046 | 1,936 | 2,061 | 2,420 | 2,456 | |
| Expenses | Rs m | 1,543 | 1,624 | 1,614 | 1,756 | 1,619 | 1,717 | 2,006 | 1,989 | |
| Gross profit | Rs m | 184 | 186 | 248 | 281 | 300 | 337 | 408 | 465 | |
| Depreciation | Rs m | 69 | 76 | 83 | 78 | 76 | 89 | 93 | 104 | |
| Interest | Rs m | 47 | 40 | 48 | 57 | 71 | 54 | 35 | 44 | |
| Profit before tax | Rs m | 81 | 75 | 123 | 156 | 171 | 202 | 286 | 319 | |
| Tax | Rs m | 14 | 19 | 38 | 45 | 264 | 51 | 72 | 52 | |
| Profit after tax | Rs m | 67 | 56 | 86 | 110 | -94 | 151 | 213 | 267 | |
| Gross profit margin | % | 10.7 | 10.3 | 13.3 | 13.8 | 15.6 | 16.4 | 16.9 | 19.0 | |
| Effective tax rate | % | 16.8 | 25.2 | 30.5 | 29.1 | 154.8 | 25.5 | 25.3 | 16.3 | |
| Net profit margin | % | 3.9 | 3.1 | 4.6 | 5.4 | -4.9 | 7.3 | 8.8 | 10.9 | |
| Diluted EPS | Rs | 5.2 | 4.4 | 6.7 | 8.6 | -7.3 | 11.7 | 16.6 | 20.8 | |
| Diluted EPS (TTM) | Rs | NA | 16.6 | 19.9 | 24.9 | 12.4 | 19.7 | 29.7 | 41.9 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: NEULAND LABS 3QFY21 Result Performance Review
More Pharmaceuticals Company Quarterly Results: FRESENIUS KABI ONCO. DIVIS LABORATORIES ALEMBIC PHARMA IPCA LABS DR. REDDYS LAB
Compare NEULAND LABS With: FRESENIUS KABI ONCO. DIVIS LABORATORIES ALEMBIC PHARMA IPCA LABS DR. REDDYS LAB
Compare NEULAND LABS With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Today's Market
Sensex Falls 300 Points, Nifty Below 15,700; Adani Group Stocks Tumble(09:30 am)
Asian stock markets are mixed today in holiday-thinned trading as investors prepared for a key Federal Reserve meeting later in the week.
Views on news
NEULAND LABS Announces Quarterly Results (3QFY21); Net Profit Up 141.5% (Quarterly Result Update)
Feb 3, 2021 | Updated on Feb 3, 2021For the quarter ended December 2020, NEULAND LABS has posted a net profit of Rs 267 m (up 141.5% YoY). Sales on the other hand came in at Rs 2 bn (up 20.5% YoY). Read on for a complete analysis of NEULAND LABS's quarterly results.
NEULAND LABS 2019-20 Annual Report Analysis (Annual Result Update)
Sep 2, 2020 | Updated on Sep 2, 2020Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.
Why Did Shares of Divi's Lab Rally Today? (Views On News)
Jun 10, 2021The stock jumped 3.6% in intraday trade to hit its 52-week high.
Laurus Labs Hits New Life High. Up 500%+ in One Year (Views On News)
Jun 8, 2021Laurus Labs trades higher for the eight straight day, soars 73% in 3 months.
Jubilant Pharmova Drops 6% on Weak March Quarter Numbers (Views On News)
Jun 8, 2021Here's a rundown on the latest quarterly results of Jubilant Pharmova.
More Views on NewsMost Popular
Hotel Stocks Will Reward Investors (Fast Profits Daily)
Jun 8, 2021This is why I'm bullish on the hotel and hospitality sector.
Don't Break These 5 Intraday Trading Rules (Fast Profits Daily)
Jun 1, 2021To become a better intraday trader, follow these rules religiously.
The Most Visible Sign of India's Revival is on Two Wheels (Profit Hunter)
Jun 9, 2021Investing in the best stocks could result in wealth compounding on a massive scale.
Rs 2 Trillion Stimulus Coming to a Stock Market Near You (Profit Hunter)
Jun 2, 2021Get ready to profit from a massive stimulus that you've never seen before.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2021
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
NEULAND LABS SHARE PRICE
Jun 14, 2021 11:25 AM
TRACK NEULAND LABS
- Track your investment in NEULAND LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON NEULAND LABS
NEULAND LABS - PROCTER & GAMBLE HEALTH COMPARISON
COMPARE NEULAND LABS WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.